Methods and compositions for targeted cleavage and recombination

• US 7,888,121 B2
• Filed: 08/06/2004
• Issued: 02/15/2011
• Est. Priority Date: 08/08/2003
• Status: Active Grant

• Current Assignee: Sangamo Therapeutics, Inc.
• Original Assignee: Sangamo Biosciences, Inc.
• Inventors: Pabo, Carl O., Urnov, Fyodor, Holmes, Michael C., Miller, Jeffrey C.
• Primary Examiner(s): DUNSTON, JENNIFER ANN
• Application Number:
  US10/912,932
• Publication Number:
  US 20050064474A1
• Time in Patent Office: 2,384 Days
• Field of Search: None
• US Class Current: 435/463
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C07K 14/43595 from coelenteratae, e.g. medusae
• CPC Class Codes: C07K 14/4717 Plasma globulins, lactoglobulin
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/09 containing a nuclear localisation signal
• CPC Class Codes: C07K 2319/81 containing a Zn-finger domain for DNA binding
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 2800/80 Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
• CPC Class Codes: C12N 9/14 Hydrolases (3)
• CPC Class Codes: C12N 9/22 Ribonucleases RNAses, DNAses catalytic nucleic acids C12N15/113
• CPC Class Codes: C12Y 301/21004 Type II site-specific deoxyribonuclease (3.1.21.4)

Abstract

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.

Claims

1. A method for cleaving genomic cellular chromatin in a region of interest of an isolated cell, the method comprising:

(a) selecting first and second nucleotide sequences in the region of interest;

(b) engineering first and second zinc finger binding domains to bind to the first and second nucleotide sequences;

(c) constitutively expressing a first fusion protein in a cell, the first fusion protein comprising the first engineered zinc finger binding domain and a first FokI cleavage half-domain;

(d) constitutively expressing a second fusion protein in the cell, the second fusion protein comprising;

(i) the second zinc finger binding domain; and

(ii) a second Fold cleavage half-domain;

wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain, the first fusion protein binds to the first nucleotide sequence, the second fusion protein binds to the second nucleotide sequence located between 2 and 50 nucleotides from the first nucleotide sequence, and the cellular chromatin is cleaved in the region of interest.

2. The method of claim 1, wherein cleavage occurs between the first and second nucleotide sequences.

3. A method for cleaving genomic cellular chromatin in a region of interest in an isolated cell, the method comprising:

(a) selecting the region of interest;

(b) engineering a first zinc finger binding domain to bind to a first nucleotide sequence in the region of interest;

(c) engineering a second zinc finger binding domain to bind to a second nucleotide sequence in the region of interest, wherein the second sequence is located between 2 and 50 nucleotides from the first sequence;

(d) constitutively expressing a first fusion protein in a cell, the first fusion protein comprising the first zinc finger binding domain and a first FokI cleavage half-domain; and

(e) constitutively expressing a second fusion protein in the cell, the second fusion protein comprising the second zinc finger binding domain and a second FokI cleavage half domain;

wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain, the first fusion protein binds to the first nucleotide sequence, and the second fusion protein binds to the second nucleotide sequence, and further wherein said binding positions the cleavage half-domains such that the cellular chromatin is cleaved in the region of interest.

4. The method of claim 3, wherein cleavage occurs between the first and second nucleotide sequences.

5. The method of claim 3 wherein the cellular chromatin is in a chromosome.

6. A method for altering a first nucleotide sequence in a region of interest in cellular chromatin in an isolated cell, the method comprising:

(a) engineering a first zinc finger binding domain to bind to a second nucleotide sequence in the region of interest, wherein the second sequence comprises at least 9 nucleotides;

(b) engineering a second zinc finger binding domain to bind to a third nucleotide sequence, wherein the third sequence comprises at least 9 nucleotides and is located between 2 and 50 nucleotides from the second sequence;

(c) constitutively expressing a first fusion protein in a cell, the first fusion protein comprising the first zinc finger binding domain and a first FokI cleavage half-domain;

(d) constitutively expressing a second fusion protein in the cell, the second fusion protein comprising the second zinc finger binding domain and a second FokI cleavage half domain, wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain; and

(e) contacting the cell with a polynucleotide comprising a fourth nucleotide sequence, wherein the fourth nucleotide sequence is homologous but non-identical with the first nucleotide sequence;

wherein binding of the first fusion protein to the second sequence, and binding of the second fusion protein to the third sequence, positions the cleavage half-domains such that the cellular chromatin is cleaved in the region of interest, thereby facilitating homologous recombination between the first nucleotide sequence and the fourth nucleotide sequence, resulting in alteration of the first nucleotide sequence.

7. The method of claim 6, wherein cleavage occurs between the second and third nucleotide sequences.

8. The method of claim 6 wherein the cellular chromatin is in a chromosome.

9. The method of claim 6 wherein the fourth nucleotide sequence contains sequences not present in the region of interest that are flanked by sequences homologous to the region of interest.

10. The method of claim 6, wherein the first nucleotide sequence comprises a mutation in a gene.

11. The method of claim 10, wherein the mutation is selected from the group consisting of at least one of a point mutation, a substitution, a deletion and an insertion.

12. The method of claim 10 wherein the fourth nucleotide sequence comprises the wild-type sequence of the gene.

13. The method of claim 10 wherein the cellular chromatin is cleaved at a site located within 100 nucleotides on either side of the mutation.

14. The method of claim 6 wherein, in step (e), the polynucleotide is linear.

15. The method of claim 6 wherein, in step (e), the polynucleotide is circular.

16. The method of claim 6 wherein, in step (e), the polynucleotide is double-stranded.

17. The method of claim 6 wherein, in step (e), the polynucleotide is single-stranded.

18. The method of claim 6 wherein, in step (e), the cell is contacted with a virus comprising the polynucleotide.

19. The method of claim 18, wherein the virus is an adenovirus or an adeno-associated virus.

20. The method of claim 6 wherein, in steps (c) and (d), the cell is contacted with two polynucleotides, the first polynucleotide encoding the first fusion protein and the second polynucleotide encoding the second fusion protein.

21. The method of claim 6 wherein, in steps (c) and (d), the cell is contacted with a polynucleotide encoding two fusion proteins, the first fusion protein comprising the first zinc finger binding domain and a first cleavage half-domain and the second fusion protein comprising the second zinc finger binding domain and a second cleavage half-domain.

22. The method of claim 6 wherein the cell is arrested in the G2 phase of the cell cycle.

23. The method of claim 6 wherein the near edges of the second and third nucleotide sequences are separated by 6 base pairs.

24. The method of claim 23 wherein, in at least one of the fusion proteins, the amino acid sequence between the zinc finger binding domain and the cleavage half-domain (Z-C linker) consists of 4 amino acid residues.

25. The method of claim 6 wherein the second and third nucleotide Sequences are present in the polynucleotide comprising the fourth nucleotide sequence.

26. The method of claim 25, wherein the fourth polynucleotide sequence is cleaved.

27. The method of claim 6, wherein the first nucleotide sequence is Converted to the fourth nucleotide sequence.

28. The method of claim 27 wherein, in steps (c) and (d), the cell is contacted with two polynucleotides, the first polynucleotide encoding the first fusion protein and the second polynucleotide encoding the second fusion protein.

29. A method for altering a first nucleotide sequence in a region of interest in cellular chromatin in an isolated cell, the method comprising:

(a) engineering a zinc finger binding domain to bind to a second nucleotide sequence in the region of interest, wherein the second sequence comprises at least 9 nucleotides;

(b) constitutively expressing a fusion protein in a cell, the fusion protein comprising the zinc finger binding domain and two FokI cleavage half-domains, wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain; and

(c) contacting the cell with a polynucleotide comprising a third nucleotide sequence, wherein the third nucleotide sequence is homologous but non-identical with the first nucleotide sequence;

wherein the fusion protein binds to the second sequence and cleaves the cellular chromatin in the region of interest, thereby facilitating homologous recombination between the first nucleotide sequence and the third nucleotide sequence, resulting in alteration of the first nucleotide sequence.

30. A method for altering a first nucleotide sequence in a region of interest in cellular chromatin in an isolated cell, the method comprising:

(a) engineering a first zinc finger binding domain to bind to a second nucleotide sequence in the region of interest, wherein the second sequence comprises at least 9 nucleotides;

(b) providing a second zinc finger binding domain to bind to a third nucleotide sequence, wherein the third sequence comprises at least 9 nucleotides and is located between 2 and 50 nucleotides from the second sequence;

(c) constitutively expressing a first fusion protein in a cell, the first fusion protein comprising the first zinc finger binding domain and a first FokI cleavage half-domain; and

(d) constitutively expressing a second fusion protein in the cell, the second fusion protein comprising the second zinc finger binding domain and a second FokI cleavage half domain, wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain;

wherein the first fusion protein binds to the second sequence, and the second fusion protein binds to the third sequence, thereby positioning the cleavage half-domains such that the cellular chromatin is cleaved at a cleavage site in the first nucleotide sequence, and non-homologous end joining at the cleavage site results in alteration of the first nucleotide sequence.

31. The method of claim 30, wherein cleavage occurs between the second and third nucleotide sequences.

32. The method of claim 30 wherein the second zinc finger binding domain is engineered to bind to the third nucleotide sequence.

33. The method of claim 30 wherein the cellular chromatin is in a chromosome.

34. The method of claim 30, wherein the non-homologous end joining generates a sequence alteration in the cellular chromatin.

35. The method of claim 34, wherein the sequence alteration is selected from the group consisting of a point mutation, a substitution, a deletion and an insertion.

36. The method of claim 30 wherein, in steps (c) and (d), the cell is contacted with a polynucleotide encoding two fusion proteins, the first fusion protein comprising the first zinc finger binding domain and a first cleavage half-domain and the second fusion protein comprising the second zinc finger binding domain and a second cleavage half-domain.

37. The method of claim 30 wherein the near edges of the second and third nucleotide sequences are separated by 6 base pairs.

38. The method of claim 37 wherein, in at least one of the fusion proteins, the amino acid sequence between the zinc finger binding domain and the cleavage half-domain(Z-C linker) consists of 4 amino acid residues.